Introduction

Tangier Disease is a rare, autosomal recessive lipid storage disorder caused by mutations in the ABCA1 gene, which plays a crucial role in the efflux of cholesterol and phospholipids. This defect leads to the accumulation of cholesterol esters within various tissues, resulting in systemic manifestations such as hepatosplenomegaly, peripheral neuropathy, and lymphadenopathy. One of the lesser-known but clinically significant aspects of Tangier Disease involves its ophthalmologic manifestations, particularly corneal opacities and associated visual impairments.

While the systemic features of Tangier Disease are more frequently documented, ocular findings, especially those affecting the cornea, offer important diagnostic clues and may impact a patient’s quality of life. Corneal opacities, typically bilateral and diffuse, arise due to lipid-laden macrophages accumulating in the corneal stroma. These opacities are often stable over time but can cause mild to moderate visual disturbances, including decreased acuity, glare, and reduced contrast sensitivity.

A thorough ophthalmologic evaluation is therefore essential for patients with Tangier Disease. Recognising and understanding these ocular signs not only aids in diagnosis but also in the holistic management of this multisystem disorder. This review focuses on the corneal changes and their visual consequences in Tangier Disease, drawing on current literature, clinical findings, and the importance of interdisciplinary care.¹

Pathophysiology of Tangier disease

Mutations in the ABCA1 cause Tangier Disease (ATP-binding cassette transporter A1) gene, which is essential for the transport of cholesterol and phospholipids across cell membranes to lipid-poor apolipoproteins, particularly ApoA-I. This process is a critical step in the formation of high-density lipoprotein (HDL), often referred to as "good cholesterol." In Tangier Disease, defective or absent ABCA1 function leads to severely reduced HDL levels and impaired cholesterol efflux. As a result, cholesterol esters accumulate in various tissues, including the liver, spleen, lymph nodes, peripheral nerves, and occasionally the eyes. This lipid buildup disrupts normal cellular function and gives rise to the multisystem features of the disease, including hepatosplenomegaly, neuropathy, and ocular changes such as corneal opacities.²

Ophthalmologic manifestations of Tangier disease

In Tangier Disease, one of the most notable ocular findings is the presence of corneal opacities, which are typically bilateral, diffuse, and located in the stromal layer of the cornea. These opacities result from the accumulation of cholesterol esters and lipid-laden macrophages in corneal tissues due to defective cholesterol transport. While often asymptomatic, some patients may experience mild visual disturbances such as blurred vision, glare, or reduced contrast sensitivity. The opacities are generally non-progressive or slowly progressive and rarely lead to significant vision loss. Other ocular structures are usually not involved, and retinal changes are uncommon. Regular eye examinations can help monitor these changes and support overall disease management.³

Corneal opacities in Tangier disease

Appearance

• Bilateral, diffuse, and symmetrical
• Located primarily in the corneal stroma
• May appear as a hazy or milky clouding of the cornea

Cause

• Accumulation of cholesterol esters and lipid-laden macrophages in corneal tissue
• Due to defective ABCA1-mediated cholesterol efflux

Onset and progression

• Often detected in childhood or early adulthood
• Typically non-progressive or very slowly progressive

Visual impact

• Usually mild visual impairment
• Symptoms may include glare, halos, or reduced contrast sensitivity
• Rarely leads to significant vision loss

Diagnosis

• Detected on slit-lamp examination
• Confocal microscopy or anterior segment OCT may help visualise lipid deposits

Differential diagnosis

• Needs to be distinguished from other causes of corneal clouding (e.g., Schnyder corneal dystrophy, cystinosis)

Management

• No specific ocular treatment required
• Regular monitoring; supportive care if symptomatic⁴

Visual impairments in Tangier disease 

Cause

• Primarily due to corneal opacities that scatter light and reduce visual clarity

Symptoms

• Mild to moderate blurry vision
• Glare sensitivity, especially in bright light
• Reduced contrast sensitivity
• Rare reports of halos or difficulty with night vision

Severity

• Usually mild and non-progressive
• Most patients retain functional vision

Progression

• Visual symptoms typically remain stable over time
• Severe vision loss is rare

Impact

• May slightly affect daily activities in some patients, particularly in low-light or high-glare conditions

Management

• Supportive care, such as anti-glare lenses or lubricating drops
• No surgical or invasive treatments are typically required⁵

Diagnostic workup 

Clinical history and examination

• Assess for systemic signs (e.g., neuropathy, enlarged tonsils, hepatosplenomegaly)
• Slit-lamp examination to detect corneal opacities

Ocular imaging

• Anterior segment OCT or confocal microscopy may show stromal deposits
• Helps assess the depth and extent of corneal involvement

Visual function tests

• Visual acuity testing, contrast sensitivity, and glare testing to evaluate the impact on vision

Laboratory tests

• Lipid panel: Markedly low or absent HDL cholesterol
• Genetic testing for ABCA1 gene mutations confirms the diagnosis

Systemic evaluation

• Neurological exam, abdominal imaging, and evaluation for lipid accumulation in other tissues

Family history

• Important due to autosomal recessive inheritance pattern ^[6]

Management and follow-up 

Ocular management

• No specific treatment for corneal opacities
• Supportive care if symptomatic (e.g., lubricating eye drops, anti-glare lenses)

Visual monitoring

• Regular eye exams to monitor corneal changes and visual function
• Check for any progression or impact on daily activities
  

Systemic management

• Focus on managing the underlying disease (e.g., lipid control, neuropathy)
• Multidisciplinary care involving ophthalmologists, lipid specialists, and genetic counsellors

Patient education

• Reassure patients that visual symptoms are usually mild and stable
• Encourage compliance with follow-up for both ocular and systemic monitoring

Genetic counselling

• Recommended for affected individuals and family members due to autosomal recessive inheritance⁷

Case reports and literature review 

Published case reports

• Several case reports describe patients with bilateral corneal opacities as an early or incidental finding in Tangier Disease
• Often diagnosed in childhood or early adulthood, sometimes before systemic symptoms fully develop

Common patterns

• Diffuse stromal clouding, typically stable over time
• Visual acuity is often preserved or mildly reduced
• Ocular findings help prompt further systemic and genetic evaluation

Rarity of retinal involvement

• Retinal abnormalities are rarely reported, highlighting the cornea as the main ocular site affected

Clinical importance

• Eye findings may serve as a diagnostic clue in undiagnosed cases
• Literature emphasises the role of interdisciplinary care in managing patients

Research gaps

• A limited number of cases are reported due to the rarity of the disease
• Need for more long-term studies on the progression of ocular findings⁸

Summary

In Tangier Disease, corneal opacities are a notable and often early ophthalmologic manifestation, arising from lipid accumulation within the corneal stroma due to impaired cholesterol transport. Although these opacities are typically bilateral, non-progressive, and cause only mild visual disturbances, they can serve as important diagnostic indicators in patients with otherwise nonspecific systemic symptoms. Visual impairments, when present, are generally limited to glare sensitivity and reduced contrast, with significant vision loss being rare. Because of their diagnostic value, ocular findings should not be overlooked and warrant comprehensive systemic evaluation. Regular ophthalmologic follow-up, along with supportive care, contributes to preserving visual function and enhancing quality of life. A multidisciplinary approach is key to managing this rare genetic disorder effectively.